Nippon India Pharma Fund

Ans. The NAV (net asset value) of Nippon India Pharma Fund (direct plan, growth option) is ₹661.0746 as on 12 Nov 2026. Mutual fund NAVs are published once a day, after the market closes.

Ans. Nippon India Pharma Fund has delivered 18.65% CAGR over the past 3 years against a category average of 22.81% and returned 14.91% over the past year. It manages ₹9,087.25 crore (AUM) as on 12 Nov 2026. Its riskometer level is Very High. Past returns do not indicate future returns.

Ans. Mutual fund taxation depends on the scheme type and investment holding period.
Taxation on equity funds: For equity funds (funds that invest at least 65% of the corpus in Indian stocks), if the holding period is more than 12 months, LTCG (Long Term Capital Gains) tax is applicable. For units sold within 12 months of purchase, STCG (Short Term Capital Gains) Tax is applicable.
LTCG tax on equity-oriented schemes is 12.5% on capital gains over ₹1.25 lakh (as per the latest update in Budget 2024).
STCG tax applicable on the sale of units of equity-oriented mutual fund schemes is 20%.

Ans. There is no lock-in period on Nippon India Pharma Fund. An exit load applies: 1% on or before 1M, Nil after 1M.

Ans. The expense ratio of Nippon India Pharma Fund (direct plan) is 0.99% a year. It is deducted from the fund's assets and is already reflected in the NAV.